Inhibitor of indole production by tryptophan indole-lyase
Patent Information
- Application Number
- JP2023086848
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2023-05-26
- Publication Date
- 2024-12-06
- Estimated Expiration
- 2043-05-26
AI Technical Summary
【0018】 本件ジケトピペラジン化合物は、TIL産生菌由来のTILによるインドール生成を阻害する作用を有する。また、本件ジケトピペラジン化合物は、食物由来の2,5-ジケトピペラジン類を包含していることから、摂取したときの安全性が高い。このため、本件ジケトピペラジン化合物を摂取すると、腸などの生体内のTIL産生菌におけるTILによって生成されるインドールを前駆体とする尿毒症物質に起因する症状又は疾患の予防·治療効果が得られる。
Smart Images

Figure 2024169964000026 
Figure 2024169964000027 
Figure 2024169964000028
Abstract
Description
[Technical field]
[0001] The present invention relates to an inhibitor of indole production by tryptophan indole-lyase (hereinafter sometimes referred to as "TIL") using L-tryptophan as a substrate, which contains a specific 2,5-diketopiperazine or a derivative thereof (hereinafter sometimes referred to as "the present diketopiperazine compound") as an active ingredient. [Background technology]
[0002] Diabetic nephropathy is one of the complications that develop as type 2 diabetes progresses, which has the largest number of patients among all types of diabetes, and is a disease in which kidney function declines. Treating diabetic nephropathy costs as much as 1.5 trillion yen per year, the largest factor being dialysis treatment. Although many causative substances of diabetic nephropathy have been identified to date, no therapeutic drugs have yet been developed.
[0003] Indoxyl sulfate, which is produced from amino acids derived from ingested food, is known to be one of the causative substances of diabetic nephropathy. The present inventors have reported that 2-aza-DL-tyrosine reduces the concentration of indoxyl sulfate in the blood and exerts an effect of improving diabetic nephropathy (Patent Document 1).
[0004] In addition, it is known that indole, a precursor of indoxyl sulfate, is produced from L-tryptophan by tryptophan indole lyase (TIL) of enterobacteria present in the intestine. The produced indole is converted to indoxyl sulfate through metabolism in the body, so it is expected that if the production of indole by TIL can be inhibited, the concentration of indoxyl sulfate will be reduced and diabetic nephropathy can be improved. Amide derivatives having a specific structure have been reported as substances having tryptophanase (corresponding to TIL) inhibitory activity (Patent Document 2). Recently, the present inventors have also reported that a specific sesame lignan compound (lignan compound contained in sesame seeds) has the effect of inhibiting the production of indole by TIL (Patent Document 3).
[0005] On the other hand, 2,5-diketopiperazine (also called "cyclic dipeptide") is a dipeptide having a cyclic structure formed by dehydration condensation of an amino group and a carboxyl group present at the terminal of a linear dipeptide, and in recent years, its various physiological activities have attracted attention. For example, it has been reported that certain diketopiperazines have the effect of improving the moisturizing function of the skin (Patent Document 4), the effect of activating or suppressing the activity of the sympathetic nerves of the skin (Patent Document 5), and the effect of dilating blood vessels (Patent Document 6). However, the relationship between 2,5-diketopiperazines and the inhibition of indole production by TIL has not been known until now. [Prior art documents] [Patent documents]
[0006] [Patent Document 1] International Publication No. 2018 / 079832 Brochure [Patent Document 2] International Publication No. 2018 / 155398 Brochure [Patent Document 3] JP 2022-135978 A [Patent Document 4] International Publication No. 2016 / 063901 Brochure [Patent Document 5] JP 2022-48337 A [Patent Document 6] JP 2018-16612 A Summary of the Invention [Problem to be solved by the invention]
[0007] An object of the present invention is to provide a low molecular weight compound which is highly safe when ingested and has the effect of inhibiting indole production by TIL. [Means for solving the problem]
[0008] As a result of intensive research by the present inventors to solve the above problems, they found that a specific 2,5-diketopiperazine has an effect of inhibiting indole production by TIL using L-tryptophan as a substrate. Furthermore, they confirmed that 2,5-diketopiperazine having an effect of inhibiting indole production by TIL inhibits indole production by TIL in TIL-producing bacteria without affecting the growth of the TIL-producing bacteria. The present invention has been completed based on these findings.
[0009] That is, the present invention is as follows. [1] An inhibitor of indole production by tryptophan indole lyase, comprising one or more compounds selected from the group consisting of compounds represented by the following formula (I) and physiologically acceptable salts thereof:
[0010] [ka]
[0011] In formula (I), R 1 and R 2 each independently represents H or a C1-C6 alkyl group, R 3 and R 4 each independently represents H; or a C1-C6 alkyl group which may have at least one group selected from the group consisting of a hydroxy group, a phenyl group, a hydroxyphenyl group, an S-CH3 group, an NH2 group, a carboxy group, a carbamoyl group, a guanidino group, and an N-containing heteroaryl group; R 1 and R 3 may form a ring via a C2-C4 alkylene group which may have a hydroxy group, R 2 and R 4 may form a ring via a C2-C4 alkylene group which may have a hydroxy group. [2] The inhibitor according to the above-mentioned [1], wherein the compound represented by formula (I) is a compound represented by the following formula (I-1), formula (I-2), formula (I-3), formula (I-4), or formula (I-5).
[0012] [ka]
[0013] [ka]
[0014] [ka]
[0015] [ka]
[0016] [ka] [3] The inhibitor according to [1] or [2] above, wherein the compound exerts a mixed inhibition on indole production by tryptophan indole lyase. [4] The inhibitor according to any one of [1] to [3] above, which is a pet feed or food or drink.
[0017] In another embodiment of the present invention, A method for preventing or treating a symptom or disease caused by a uremic substance (e.g., indoxyl sulfate, indole-3-acetic acid, the same applies below) whose precursor is indole produced by TIL in a TIL-producing bacterium in a mammalian living body, comprising a step of ingesting (administering) the diketopiperazine compound to a mammal in need of the prevention or treatment of the symptom or disease; or The diketopiperazine compound for use in the prevention or treatment of symptoms or diseases caused by uremic substances whose precursor is indole produced by TIL in TIL-producing bacteria in a mammalian living body; Use of the diketopiperazine compound for producing an agent for preventing or treating a symptom or disease caused by a uremic substance having an indole precursor produced by TIL in a TIL-producing bacterium in a mammalian living body; Use of the diketopiperazine compound for the manufacture of an inhibitor of indole production by TIL; Examples include: Effect of the Invention
[0018] The diketopiperazine compound has an effect of inhibiting indole production by TIL derived from TIL-producing bacteria. In addition, since the diketopiperazine compound contains 2,5-diketopiperazines derived from food, it is highly safe when ingested. Therefore, when the diketopiperazine compound is ingested, it is possible to obtain a preventive and therapeutic effect against symptoms or diseases caused by uremic substances whose precursor is indole produced by TIL in TIL-producing bacteria in the intestine or other living organisms. [Brief description of the drawings]
[0019] [Figure 1] This figure shows the results of indole concentration measurement after incubating TIL and its substrate L-tryptophan in the presence of five types of 2,5-diketopiperazines (cGA ["Cyclo-Gly-Ala" in the figure], cGE ["Cyclo-Gly-Glu" in the figure], cGL ["Cyclo-Gly-Leu" in the figure], cGP ["Cyclo-Gly-Pro" in the figure], and cGS ["Cyclo-Gly-Ser" in the figure]). "*" and "**" in the figure indicate that there is a statistically significant difference (p<0.05 and p<0.01), respectively, compared to the results when incubated in the absence of the five types of 2,5-diketopiperazines ("No inhibitor" in the figure) (the same applies below). [Diagram 2]This figure shows the results of indole concentration measurement in the culture medium of TIL-producing bacteria derived from Citrobacter koseri JCM1658 strain (Figure 2A) or Morganella morganii JCM1672 strain (Figure 2B), which were incubated for 20 minutes in the presence or absence of L-tryptophan, a TIL substrate, and in the presence or absence of 2,5-diketopiperazine (cGP). [Diagram 3] This figure shows the results of indole concentration measurement in the culture medium of TIL-producing bacteria derived from Citrobacter koseri JCM1658 strain (Figure 3A) or Morganella morganii JCM1672 strain (Figure 3B), which were incubated for 30 minutes in the presence or absence of L-tryptophan, a TIL substrate, and in the presence or absence of 2,5-diketopiperazine (cGP). [Figure 4] This figure shows the results of incubating TIL-producing bacteria derived from Citrobacter koseri JCM1658 strain (Figure 4A) or TIL-producing bacteria derived from Morganella morganii JCM1672 strain (Figure 4B) for 0 or 90 minutes in the presence or absence of L-tryptophan, a TIL substrate, and in the presence or absence of 2,5-diketopiperazine (cGP), and calculating the number of colonies derived from the grown TIL-producing bacteria. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0020] The inhibitor of the present invention is an agent (hereinafter sometimes referred to as "the inhibitor") that contains the diketopiperazine compound of the present invention, i.e., one or more compounds selected from the compound of the following formula (I) and physiologically acceptable salts thereof, and is specified for the use "of inhibiting indole production by TIL."
[0021] [ka]
[0022] In formula (I), R 1 and R 2each independently represents H or a C1-C6 alkyl group, R 3 and R 4 each independently represents H; or a C1-C6 alkyl group which may have at least one group selected from the group consisting of a hydroxy group, a phenyl group, a hydroxyphenyl group, an S-CH3 group, an NH2 group, a carboxy group, a carbamoyl group, a guanidino group, and an N-containing heteroaryl group (i.e., a C1-C6 alkyl group; or a C1-C6 alkyl group having at least one group selected from the group consisting of a hydroxy group, a phenyl group, a hydroxyphenyl group, an S-CH3 group, an NH2 group, a carboxy group, a carbamoyl group, a guanidino group, and an N-containing heteroaryl group), R 1 and R 3 may form a ring via a C2-C4 alkylene group which may have a hydroxy group, R 2 and R 4 may form a ring via a C2-C4 alkylene group which may have a hydroxy group.
[0023] In formula (I), R 1 ~R 4 C1-C6 alkyl group, R 2 Examples of the C1 to C6 alkyl group include a methyl group, an ethyl group, an n-propyl group, an i-propyl group, an n-butyl group, an s-butyl group, an i-butyl group, a t-butyl group, an n-pentyl group, and an n-hexyl group.
[0024] In formula (I), R 3 and R 4The N-containing heteroaryl group, which is one of the substituents of the C1-C6 alkyl group, includes a 5-7-membered monocyclic or polycyclic aromatic heterocycle having 1-4 nitrogen atoms as heteroatoms, and a fused ring formed by condensing a benzene ring with a 5-7-membered heterocycle having 1-4 nitrogen atoms as heteroatoms. Examples of the fused ring include pyridinyl, imidazolyl, pyrimidinyl, pyrazolyl, triazolyl, pyrazinyl, tetrazolyl, pyrrolyl, quinolinyl, indolyl, benzimidazolyl, pyridazinyl, triazinyl, etc.
[0025] The diketopiperazine compound of the present invention includes stereoisomers (eg, enantiomers), isomers such as tautomers, solvates, hydrates, and mixtures thereof.
[0026] Examples of physiologically acceptable salts of the compound represented by the above formula (I) include inorganic salts such as sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, nitrate, phosphate, monohydrogenphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate, chloride, bromide, iodide, and fluoride; acetate, propionate, decanoate, caprylate, acrylate, formate, isobutyrate, caprate, heptanoate, propiolate, oxalate, malonate, succinate, suberate, fumarate, maleate, benzoate, chlorobenzoate, methionate, benzoate, benzoate, chlorobenzoate, ... Examples of the salt include organic salts such as phenylbenzoate, dinitrobenzoate, hydroxybenzoate, methoxybenzoate, phthalate, terephthalate, benzenesulfonate, toluenesulfonate, chlorobenzenesulfonate, xylenesulfonate, phenylacetate, phenylpropionate, phenylbutyrate, citrate, lactate, hydroxybutyrate, glycolate, malate, and tartrate; alkali metal salts such as sodium salt and potassium salt; alkaline earth metal salts such as calcium salt and magnesium salt; and ammonium salt.
[0027] Specific examples of the diketopiperazine compound of the present invention include compounds represented by the following formula (I-1), (I-2), (I-3), (I-4), (I-5), or (I-6). Since the effects of these compounds have been demonstrated in the present Examples described later, the compounds represented by the following formula (I-1), (I-2), (I-3), (I-4), or (I-5) are preferred. [ka]
[0028] [ka]
[0029] [ka]
[0030] [ka]
[0031] [ka]
[0032] [ka]
[0033] The diketopiperazine compound of the present invention may be a commercially available product or may be synthesized by a known method.
[0034] As a method for synthesizing the present diketopiperazine compound by a known production method, for example, a method in which a dipeptide represented by the following formula (II) is heated in an organic solvent while removing water by distillation according to the method described in JP-A-2003-531197 can be mentioned.
[0035] [ka]
[0036] In formula (II), R 1 ~R 4 are R in formula (I), 1 ~R 4 It has the meaning:
[0037] The organic solvent may be any solvent that forms a low-boiling azeotrope with water, and examples thereof include acetonitrile, allyl alcohol, benzene, benzyl alcohol, n-butanol, 2-butanol, t-butanol, butyl acetate, carbon tetrachloride, chlorobenzene, chloroform, cyclohexane, 1,2-dichloroethane, diethyl acetal, dimethyl acetal, ethyl acetate, heptane, methyl isobutyl ketone, 3-pentanol, toluene, and xylene.
[0038] The reaction temperature is usually 50 to 200° C., and preferably 80 to 150° C. The pH at which the cyclization is carried out is usually 2 to 9, and preferably 3 to 7.
[0039] The dipeptide represented by formula (II) can be obtained, for example, by a dehydration condensation reaction between glycine and another amino acid or a derivative thereof.
[0040] Alternatively, it can be produced by heating an aqueous solution containing a linear dipeptide or linear tripeptide at 70 to 100° C. under a pressure of 0.5 MPa or less, according to the method described in Japanese Patent No. 5,456,876.
[0041] 2,5-Diketopiperazine is known to be found in fruits and products involving fermentation or cooking processes, such as black currants, cordyceps, cheese, braised beef, and chicken essence, and can be obtained as part of food extracts or concentrates.
[0042] Ingestion of the diketopiperazine compound, which is the active ingredient of the inhibitor, can provide preventive and therapeutic effects against symptoms or diseases caused by uremic substances whose precursor is indole produced by TIL in TIL-producing bacteria in the body such as the intestine. Therefore, suitable examples of the inhibitor include those specified for the use of "preventing or ameliorating (treating) symptoms or diseases caused by uremic substances whose precursor is indole produced by tryptophan indole lyase in tryptophan indole lyase-producing bacteria in the body of a mammal" (hereinafter, sometimes referred to as "the preventive / ameliorating agent").
[0043] As used herein, mammals include humans and non-human mammals (e.g., monkeys; mice; rats; pets such as dogs and cats; livestock such as rabbits, pigs, horses, cows, sheep, goats, and deer).
[0044] When the present inhibitor is ingested by a non-human mammal or administered to a non-human mammal, the present diketopiperazine compound may be used alone as a feed for a non-human mammal, or may be mixed with an additive and used in the form of a composition (i.e., a feed composition for a non-human mammal). When the present inhibitor is ingested by a non-human mammal or human, or may be administered to a non-human mammal or human, the present diketopiperazine compound may be used alone as a food or drink or a pharmaceutical (preparation), or may be mixed with an additive and used in the form of a composition (a food or drink composition or a pharmaceutical composition). Examples of the above-mentioned food or drink include health foods (functional foods, nutritional supplements, health supplements, nutritionally enhanced foods, nutritionally adjusted foods, supplements, etc.), health functional foods (foods for specified health uses, foods with nutritional functions, foods with functional claims, etc.), and herbal medicines. Pet feed and food or drink are preferred as the present inhibitor.
[0045] As used herein, "TIL" refers to an enzyme that catalyzes reaction 1 (L-tryptophan + water [HO] → indole + pyruvic acid + ammonia [NH]) and the reverse reaction 2 (indole + pyruvic acid + ammonia [NH] → L-tryptophan + water [HO]), as shown in the following reaction formula:
[0046] [ka]
[0047] The diketopiperazine compound of the present invention inhibits at least reaction 1 in the above reaction formula, and thereby has the effect of inhibiting indole production by TIL.
[0048] In the above reaction scheme, the type of inhibition by the diketopiperazine compound of the present invention is not particularly limited, and examples thereof include competitive inhibition, uncompetitive inhibition, mixed inhibition, and the like.
[0049] As used herein, the term "competitive inhibition" refers to an inhibition mode in which an inhibitor (the diketopiperazine compound) binds to a substrate-binding site of an enzyme (TIL) that is not bound to a substrate (L-tryptophan). Note that in competitive inhibition, the inhibitor does not bind to the enzyme-substrate complex.
[0050] As used herein, "uncompetitive inhibition" refers to a form of inhibition in which an inhibitor (the diketopiperazine compound) binds only to an enzyme-substrate complex, but not to an enzyme (TIL) that is not bound to a substrate (L-tryptophan).
[0051] As used herein, the term "mixed inhibition" refers to a form of inhibition in which an inhibitor (the diketopiperazine compound) binds to both an enzyme (TIL) that is not bound to a substrate (L-tryptophan) and to the enzyme-substrate complex with different inhibition constants (Ki).
[0052] As the diketopiperazine compound of the present invention, a compound that inhibits indole production by TIL can be preferably exemplified, since the effect of the compound has been demonstrated in the Examples described later.
[0053] The origin of the TIL is not particularly limited, but examples thereof include TIL produced by TIL-producing bacteria (more specifically, TIL-producing bacteria in various organs or tissues in a mammalian living body), since the effect of the TIL has been demonstrated in the present Example described later. Therefore, the present inhibitor can be advantageously applied as a preventive or therapeutic agent for symptoms or diseases caused by uremic substances having as a precursor indole produced by TIL in TIL-producing bacteria in a mammalian living body.
[0054] As used herein, "TIL-producing bacteria" is preferably TIL-producing enterobacteria, and specific examples thereof include bacteria of the genus Escherichia (e.g., Escherichia coli [E. coli], Escherichia albertii [E. albertii]), bacteria of the genus Morganella (e.g., Morganella morganii [M. morganii]), bacteria of the genus Bacteroides (e.g., Bacteroides thetaiotaomicron [B. thetaiotaomicron], Bacteroides ovatus [B. ovatus]), bacteria of the genus Citrobacter (e.g., Citrobacter koseri [C. koseri]), and the like.
[0055] As used herein, examples of "various organs or tissues" include the large intestine (colon or rectum), stomach, liver, heart, brain, spinal cord, lung, esophagus, duodenum, small intestine, skin, prostate, bladder, uterus, kidney, pancreas, spleen, trachea, bronchi, gallbladder, bile duct, etc.
[0056] In the present specification, examples of the "symptoms or diseases" in the "symptoms or diseases caused by uremic substances whose precursor is indole produced by tryptophan indole lyase in tryptophan indole lyase-producing bacteria in the living body of a mammal" include, for example, abnormal test values in a health checkup (e.g., a state showing deterioration in renal function-related indicators such as an increase in creatinine level, a decrease in estimated glomerular filtration rate [eGFR], and positive proteinuria), digestive system abnormalities such as loss of appetite, nausea, vomiting, halitosis, stomatitis, and enteritis, and nervous system abnormalities such as apathy, apathy, decreased memory, depression, somnolence, coma, polyneuropathy, (developmental) coordination disorder, and anorexia. system abnormalities; circulatory system abnormalities such as arteriosclerosis, anemia, erythropoietic disorders, hypertension, ischemic heart disease, pericarditis, myocarditis, (blood) coagulation disorders, heart failure, and cardiovascular disorders; skin abnormalities (diseases) such as pigmentation, pruritus, subcutaneous bleeding, skin atrophy, psoriasis, atopy, and alopecia; renal dysfunction such as albuminuria, acute renal failure, acute tubular necrosis, renal anemia, chronic renal failure, tubular interstitial damage, acute nephritis, chronic nephritis, nephrosis, diabetic nephropathy, arteriosclerotic nephropathy, renal bone disorders (e.g., renal osteodystrophy), and overflow; stroke; myocardial infarction; cancer; autism; immunodeficiency; bone disorders; hyperparathyroidism; insulin resistance; malnutrition; inflammation; tremors; and the like. The above symptoms or diseases also include symptoms or diseases involving LPS (Lipopolysaccharide), such as IgA nephropathy, polycystic kidney disease, liver dysfunction (e.g., fulminant hepatitis, fatty liver, NASH, NAFLD), and cancer (e.g., bile carcinogenesis); inflammatory bowel diseases, such as ulcerative colitis and Crohn's disease; arteriosclerosis-related diseases; autoimmune diseases, such as lupus, scleroderma, and rheumatism; obesity; metabolic syndrome; diabetes; autism; Parkinson's disease; Alzheimer's disease; and sarcopenia. The above symptoms or diseases do not include symptoms or diseases caused by uremic substances whose precursor is indole produced by TIL in TIL-producing bacteria, but by factors other than these uremic substances.
[0057] The subjects for taking (administering) the inhibitor of the present invention are not particularly limited as long as they are mammals, and typically include mammals in need of inhibition of indole production by TILs, and mammals in need of prevention or improvement (treatment) of symptoms or diseases caused by uremic substances whose precursor is indole produced by tryptophan indole lyase in tryptophan indole lyase-producing bacteria in the mammalian body.
[0058] The dosage form of the inhibitor of the present invention may be oral administration, in which the inhibitor is ingested (administered) in the form of powder, granules, tablets, capsules, syrup, jelly, gum, troche, gummies, film, etc., or parenteral administration, in which the inhibitor is ingested (administered) in the form of topical skin preparation, transdermal preparation, transmucosal preparation, nasal preparation, enteral preparation, injection, suppository, inhalant, patch, etc. Such parenteral administration includes administration in the form of liquid preparation, semisolid preparation, etc., via a gastrostomy or other fistula method, or via tube feeding using a nasogastric tube.
[0059] The inhibitor of the present invention for oral ingestion (administration) can be a sustained release agent or an enteric agent. Such an enteric agent can be obtained, for example, by filling granules containing the diketopiperazine compound of the present invention as an active ingredient with an enteric coating (i.e., a coating mainly composed of a base [enteric ingredient] that is resistant to gastric juice and dissolves in the small intestine), or by adding a lubricant to granules containing the diketopiperazine compound of the present invention as an active ingredient, compressing the resulting tablets, and coating the tablets with an enteric coating.
[0060] Methods for obtaining the present inhibitor in tablet form include, for example, a method in which the active ingredient, the present diketopiperazine compound, is mixed with any ingredients (additives) that may be added as necessary, and then the mixture is compressed to obtain tablets, or a method in which the tablet obtained after compression is coated with an enteric ingredient (enteric-coated method), and the latter method is preferred.
[0061] Examples of the enteric ingredient include shellac, zein, hydroxymethylcellulose phthalate, carboxymethylcellulose, carboxymethylethylcellulose, cellulose acetate phthalate, methacrylic acid copolymer, water-insoluble ethylcellulose, aminoalkylmethacrylate copolymer, brewer's yeast cell wall (e.g., product name Yeasttrap, etc.), tapioca starch, gelatin, pectin, etc., among which shellac is preferred. It should be noted that whether or not it is an enteric agent can be confirmed by the disintegration test method of the 14th revised Japanese Pharmacopoeia.
[0062] The intake amount of the diketopiperazine compound contained in the inhibitor is appropriately determined depending on the age, body weight, sex, symptoms, drug sensitivity, species, etc. of the mammal to be ingested (administered), and the concentration converted to the diketopiperazine compound is, for example, in the range of 0.1 μg to 200 mg / kg (body weight) / day. The inhibitor may be ingested once or in multiple doses (e.g., 2 to 4 times) per day.
[0063] In the present specification, examples of "additives" include physiologically acceptable ordinary carriers, binders, stabilizers, excipients, diluents, pH buffers, disintegrants, isotonicity agents, coating agents, solubilizers, lubricants, glidants, solubilizers, flavorings, sweeteners, solvents, gelling agents, nutrients, various oils, surfactants, preservatives, antioxidants, dispersants, chelating agents, thickeners, UV absorbers, emulsion stabilizers, pH adjusters, colorants, fragrances, etc. Specific examples of such ingredients include water, physiological saline, animal fats and oils, vegetable oils, lactose, starch, gelatin, crystalline cellulose, gum, talc, magnesium stearate, hydroxypropyl cellulose, polyalkylene glycol, polyvinyl alcohol, glycerin, vitamins, minerals, lactic acid bacteria, proteins, and collagen.
[0064] The inhibitor of the present invention may contain a component other than the diketopiperazine compound as an inhibitor of indole production by TIL, but since the diketopiperazine compound alone exhibits an excellent inhibitory effect, the inhibitor may not contain the above-mentioned inhibitory components other than the diketopiperazine compound (e.g., compounds such as proteins, amino acids, DNA, RNA, polymers, etc.; plant-derived extracts [e.g., sesame lignan compounds]). The preventive / improving agent of the present invention may contain a component other than the diketopiperazine compound as an inhibitor of indole production by TIL and prevents or improves (treats) symptoms or diseases caused by uremic substances whose precursor is indole produced by TIL in TIL-producing bacteria in a mammalian living body, but since the diketopiperazine compound alone exhibits an excellent inhibitory effect and preventive or improving effect, the inhibitor may not contain the above-mentioned components other than the diketopiperazine compound (e.g., compounds such as proteins, amino acids, DNA, RNA, polymers, etc.; plant-derived extracts [e.g., sesame lignan compounds]). In addition, the present preventive / ameliorating agent may contain a component that inhibits indole production by TIL and prevents or ameliorates (treats) symptoms or diseases that are not caused by uremic substances whose precursor is indole produced by TIL in TIL-producing bacteria in a mammalian living body.
[0065] The present invention will be described in more detail below with reference to examples, but the technical scope of the present invention is not limited to these examples. EXAMPLES
[0066] 1. Confirmation that the compound inhibits indole production by TIL using L-tryptophan as a substrate Using five types of 2,5-diketopiperazines (cGP, cGS, cGL, cGE, and cGA; see Table 1) included in the subject compound, we analyzed whether the subject compound inhibits indole production by TILs using L-tryptophan (hereinafter simply referred to as "tryptophan") as a substrate.
[0067] 1-1 Materials and Methods [TIL-containing liquid] As the TIL-containing solution, a solution containing TILs derived from Citrobacter koseri (25 pkat / mL) (Sigma Aldrich) was used in the following [TIL inhibitory activity test].
[0068] [TIL inhibitory activity test] The TIL inhibitory activity test was carried out according to the following procedures (1) to (4). [1] 98 μL of a reaction buffer (containing 100 mM potassium phosphate buffer [KPB] [pH 8.0], 200 μM pyridoxal-5'-phosphate [PLP], and 1 mM 2-mercaptoethanol) containing 200 μM tryptophan and 200 μM of five kinds of 2,5-diketopiperazines (cGP [Bachem], cGS [Sigma Aldrich], cGL [Sigma Aldrich], cGE [Chem-Impex], and cGA [Combi-Blocks]) was incubated at 37° C. for 10 minutes. As a control, a reaction buffer containing tryptophan and not containing 2,5-diketopiperazine was also incubated in the same manner. [2] 2 μL of a TIL-containing solution was added to give a final concentration of 0.1 pkat / mL, and the mixture was incubated at 37° C. for 30 minutes. [3] 100 μL of a reaction stop solution (a solution containing 40% acetonitrile and 4% trifluoroacetic acid) was added, and the mixture was centrifuged (15,000×g, 10 minutes, 4° C.). [4] The supernatant was collected and subjected to mass spectrometry using LC-MS under the conditions shown in Table 2 to quantify the indole produced by TIL. The indole concentration in the reaction buffer containing no 2,5-diketopiperazine was set at 100, and the relative values of the indole concentrations in the reaction buffer containing each of the present compounds were calculated (see the vertical axis of FIG. 1).
[0069] 1-2 Results When TIL and its substrate tryptophan were incubated in the presence of five 2,5-diketopiperazines (cGP, cGS, cGL, cGE, and cGA), the amount of indole produced was significantly reduced compared to when incubated in the absence of 2,5-diketopiperazines (see Figure 1).
[0070] This result indicates that the above-mentioned five types of 2,5-diketopiperazines included in the compound of the present invention have an effect of inhibiting indole production by TIL using tryptophan as a substrate.
[0071] [Table 1]
[0072] [Table 2] EXAMPLES
[0073] 2. Inhibition mode and inhibition constant of TIL by the compound Next, the mode of inhibition of TIL by the compound in question was determined, and the inhibition constant of TIL by the compound in question (specifically, the concentration of the compound in question at which 50% inhibition of indole production by TIL using tryptophan as a substrate was observed) was calculated.
[0074] 2-1 Method The TIL inhibitory activity test of Example 1 was carried out using 200 μM of four kinds of 2,5-diketopiperazines (cGP, cGS, cGL, and cGE; see Table 1), and the indole production rate (μM / min) (hereinafter, collectively referred to as "v") was calculated. Next, v was plotted on the vertical axis and tryptophan concentration (μM) (hereinafter, referred to as [S]) on the horizontal axis, respectively, and fitting to an approximate curve was performed using SigmaPlot (manufactured by Hulinks) to calculate kinetic parameters. Then, 1 / v was plotted on the vertical axis and 1 / [S] on the horizontal axis (Lineweaver Burk plot), and the inhibition mode of TIL by various 2,5-diketopiperazines was determined from the shape of the approximate line, and the inhibition constant of TIL was calculated.
[0075] 2-2 Results As a result, it was revealed that the inhibition modes and inhibition constants (Ki) of TIL by the above four types of 2,5-diketopiperazines are as shown in Table 3.
[0076] [Table 3] EXAMPLES
[0077] 3. Confirmation that the compound inhibits indole production by TIL using tryptophan as a substrate in TIL-producing bacteria Next, it was analyzed whether the present compound inhibits indole production by TIL using tryptophan as a substrate in TIL-producing bacteria.
[0078] 3-1 Materials and Methods [TIL-producing bacteria] As TIL-producing bacteria, two representative types of intestinal bacteria that produce TIL, specifically, TIL-producing bacteria derived from Citrobacter koseri strain JCM1658 and TIL-producing bacteria derived from Morganella morganii strain JCM1672 (both from RIKEN BioResource Research Center), were used in the following [TIL inhibitory activity test].
[0079] [TIL inhibitory activity test] The TIL inhibitory activity test was carried out according to the following procedures [1] to [6]. [1] TIL-producing bacteria were cultured anaerobically in a liquid medium made by removing the agar from a semi-liquid medium for GAM sugar decomposition (manufactured by Nissui Co., Ltd.) containing 1% glycerol and 0.1% tryptophan at 37°C for 24 hours in a jar containing an Anaeropack. [2] The culture medium containing the cultured cells was centrifuged (15,000 × g, 10 minutes, 4 °C) to collect the cells. After removing the supernatant, the cells were suspended in a reaction buffer (a solution containing 100 mM KPB [pH 8.0], 200 μM PLP, and 1 mM 2-mercaptoethanol). [3] The cells were harvested by centrifugation (15,000 × g, 10 minutes, 4°C), the supernatant was removed, and the cells were suspended in fresh reaction buffer. [4] Collect the cells by centrifugation (15,000 × g, 10 min, 4 °C), remove the supernatant, and then measure the OD 600 The TIL-producing bacteria were suspended in the reaction buffer containing 0.5 mM tryptophan and 5 mM 2,5-diketopiperazine (cGP) so that the β-reactive protein ratio was 2.0 ([Substrate +, cGP +] in Fig. 2 and Fig. 3). As a comparative control, the TIL-producing bacteria were also suspended in three kinds of reaction buffers, specifically, the reaction buffer containing neither tryptophan nor 2,5-diketopiperazine (cGP) ([Substrate -, cGP -] in Fig. 2 and Fig. 3), the reaction buffer containing tryptophan and not containing 2,5-diketopiperazine (cGP) ([Substrate +, cGP -] in Fig. 2 and Fig. 3), and the reaction buffer containing not tryptophan and not containing 2,5-diketopiperazine (cGP) ([Substrate -, cGP +] in Fig. 2 and Fig. 3). [5] The cells were cultured anaerobic in a jar containing Anaeropack at 37°C for 20 minutes (Figure 2) or 30 minutes (Figure 3), and then centrifuged (15,000 x g, 10 minutes, 4°C). [6] The supernatant was passed through a 0.45 μm hydrophilic filter, and then mass spectrometry using LC-MS was performed according to the conditions shown in Table 2 to quantitate the indole concentration in the culture medium of the TIL-producing bacteria (see the vertical axis of Figures 2 and 3).
[0080] 3-2 Results When two types of TIL-producing bacteria (TIL-producing bacteria derived from Citrobacter koseri strain JCM1658 and TIL-producing bacteria derived from Morganella morganii strain JCM1672) were incubated with tryptophan, a TIL substrate, in the presence of 2,5-diketopiperazine (cGP) for 20 or 30 minutes, the amount of indole produced was significantly reduced compared to when incubated in the absence of 2,5-diketopiperazine (cGP) (see Figures 2 and 3).
[0081] These results indicate that the compounds of the present invention, such as cGP, were taken up into the cells of representative intestinal bacteria that produce TIL, and inhibited indole production by TIL using tryptophan as a substrate in the TIL-producing bacteria. EXAMPLES
[0082] 4. Confirmation that the compound does not affect the growth of TIL-producing bacteria Next, it was analyzed whether the present compounds affect the growth of TIL-producing bacteria.
[0083] 4-1 Method The growth test was carried out according to the following steps (1) to (5). [1] TIL-producing bacteria (TIL-producing bacteria derived from Citrobacter koseri JCM1658 strain and TIL-producing bacteria derived from Morganella morganii JCM1672 strain) were cultured in a liquid medium made by removing the agar from a semi-liquid medium for GAM sugar decomposition (manufactured by Nissui Co., Ltd.) containing 1% glycerol and 0.1% tryptophan, in a jar containing an Anaeropack, for 24 hours at 37°C (anaerobic culture). [2] The culture medium containing the cultured cells was centrifuged (15,000 × g, 10 minutes, 4 °C) to collect the cells. After removing the supernatant, the cells were suspended in a reaction buffer (a solution containing 100 mM KPB [pH 8.0], 200 μM PLP, and 1 mM 2-mercaptoethanol). [3] The cells were harvested by centrifugation (15,000 × g, 10 minutes, 4°C), the supernatant was removed, and the cells were suspended in fresh reaction buffer. [4] Collect the cells by centrifugation (15,000 × g, 10 min, 4 °C), remove the supernatant, and then measure the OD 600 The TIL-producing bacteria were suspended in the reaction buffer containing 0.5 mM tryptophan and 5 mM 2,5-diketopiperazine (cGP) so that the β-reactive protein ratio was 2.0 ([Substrate +, cGP +] in FIG. 4). As a comparative control, the TIL-producing bacteria were also suspended in three types of reaction buffers, specifically, the reaction buffer containing neither tryptophan nor 2,5-diketopiperazine (cGP) ([Substrate -, cGP -] in FIG. 4), the reaction buffer containing tryptophan and not containing 2,5-diketopiperazine (cGP) ([Substrate +, cGP -] in FIG. 4), and the reaction buffer containing not tryptophan and not containing 2,5-diketopiperazine (cGP) ([Substrate -, cGP +] in FIG. 4). [5] Samples incubated at 37°C for 0 or 90 minutes were diluted with 0.85% saline and then applied to a semi-liquid medium for GAM glycolysis (manufactured by Nissui Co., Ltd.). After static culture (anaerobic culture) for 24 hours in a jar containing an Anaeropack, the number of colonies that grew (CFU; Colony Forming Unit) was calculated (see the vertical axis of Figure 4).
[0084] 4-2 Results The CFU of two types of TIL-producing bacteria (TIL-producing bacteria derived from Citrobacter koseri strain JCM1658 and TIL-producing bacteria derived from Morganella morganii strain JCM1672) did not differ depending on the presence or absence of 2,5-diketopiperazine (cGP) (see FIG. 4).
[0085] This result indicates that the compounds of the present invention such as cGP inhibit indole production by TIL in TIL-producing bacteria without affecting the growth of the TIL-producing bacteria. [Industrial Applicability]
[0086] The present invention contributes to the prevention and treatment of symptoms or diseases caused by uremic substances (e.g., indoxyl sulfate, indole-3-acetic acid) whose precursor is indole produced by TIL in TIL-producing bacteria in the body.
Claims
1. An inhibitor of indole production by tryptophan indole lyase, comprising one or more compounds selected from the group consisting of compounds represented by the following formula (I) and physiologically acceptable salts thereof: 【Chemistry 1】 [In the formula, R 1 and R 2 each independently represents H or a C1-C6 alkyl group, R 3 and R 4 are each independently H; or a hydroxy group, a phenyl group, a hydroxyphenyl group, or S—CH 3 Group, NH 2 represents a C1-C6 alkyl group which may have at least one group selected from the group consisting of a carboxy group, a carbamoyl group, a guanidino group, and an N-containing heteroaryl group; R 1 and R 3 may form a ring via a C2-C4 alkylene group which may have a hydroxy group, R 2 and R 4 may form a ring via a C2-C4 alkylene group which may have a hydroxy group.]
2. The inhibitor according to claim 1, wherein the compound represented by formula (I) is a compound represented by the following formula (I-1), formula (I-2), formula (I-3), formula (I-4), or formula (I-5). 【Chemistry 2】 【Chemistry 3】 【Chemistry 4】 【Chemistry 5】 【Chemistry 6】
3. The inhibitor of claim 1 , wherein the compound exhibits mixed inhibition of indole production by tryptophan indole lyase.
4. The inhibitor according to any one of claims 1 to 3, which is a pet feed or food or drink.
Citation Information
Patent Citations
Renal insufficiency therapeutic drug and food for renal insufficient patient
JP1999209303A
Remedy for inflammatiory disease containing diketopiperazine derivative and new diketopiperazine derivative
JP2000327575A
Tryptophanase inhibitor and composition containing the inhibitor
JP2007001900A
Treatment of T cell-mediated diseases
JP2007500747A
Food for improving cognitive function
JP2020196686A
